Figure 4. hRME-6 acts as a GEF for rab5 during AP2 uncoating. (A) Western blots of HEK293T cells treated with control siRNA and siRNAs directed against hRME-6 and rabex-5. (B) Representative images of siRNA-treated cells incubated with Texas red Tfn and, after acid stripping, stained for AP2 using AP.6 mAb. The arrowheads indicate an overlap between the two shown enlarged in the inset. Bar, 10 μm. (C) Quantitation of the degree of overlap between AP2 and Texas red Tfn in cells treated with control siRNA and siRNA against hRME-6 and rabex-5. The degree of overlap between AP.6 and Texas red Tfn was set at 1 in control cells. Results are expressed as the fold change in overlap compared with control cells ± SEM and are the results of three experiments where at least 25 cells were analyzed. Values are significant at P < 0.01 (**) for control versus hRME-6 knockdown and rabex-5 versus hRME-6 knockdown.
Figure 4.

hRME-6 acts as a GEF for rab5 during AP2 uncoating. (A) Western blots of HEK293T cells treated with control siRNA and siRNAs directed against hRME-6 and rabex-5. (B) Representative images of siRNA-treated cells incubated with Texas red Tfn and, after acid stripping, stained for AP2 using AP.6 mAb. The arrowheads indicate an overlap between the two shown enlarged in the inset. Bar, 10 μm. (C) Quantitation of the degree of overlap between AP2 and Texas red Tfn in cells treated with control siRNA and siRNA against hRME-6 and rabex-5. The degree of overlap between AP.6 and Texas red Tfn was set at 1 in control cells. Results are expressed as the fold change in overlap compared with control cells ± SEM and are the results of three experiments where at least 25 cells were analyzed. Values are significant at P < 0.01 (**) for control versus hRME-6 knockdown and rabex-5 versus hRME-6 knockdown.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal